November 20, 2020
Five Chinese COVID-19 vaccine candidates are under phase-III clinical trials in countries including the UAE, Brazil, Pakistan and Peru, according to Foreign Ministry Spokesperson Zhao Lijian on Wednesday.
The five Chinese vaccines referenced include two inactivated vaccines developed by the China National Pharmaceutical Group (Sinopharm), one inactivated vaccine developed by Sinovac Biotech Co., one adenoviral vector vaccine jointly developed by the Academy of Military Sciences and the Chinese biotech company CanSino, and one recombinant protein vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy.
Dr. Fehmi Tabak, head of the Infectious Diseases and Clinical Microbiology Department at the Cerrahpasa Faculty of Medicine in Istanbul said that he is optimistic that the Phase 3 results of the Sinovac vaccine will be similar to those of the previous trials and the necessary approvals will be received soon.
(Sources: The China Report)
Đăng nhận xét